Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARVN

Arvinas Inc

Dec 05 • 04:00PM ET

12.79

+0.24 1.91 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX IONS EXEL NBIX GILD BMRN REGN ALNY SRPT BIIB

| Held by: VTI IWM VXF IWN IBB SCHA XPH VTWO PRFZ IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.80	Insider Own	13.92%	Shs Outstand	70.80M	Perf Week	1.63%
Market Cap	821.43M	Forward P/E	-	EPS next Y	-3.00	Insider Trans	0.24%	Shs Float	55.29M	Perf Month	33.65%
Enterprise Value	43.33M	PEG	-	EPS next Q	-0.51	Inst Own	89.06%	Short Float	14.73%	Perf Quarter	61.08%
Income	-58.50M	P/S	2.63	EPS this Y	74.27%	Inst Trans	-13.10%	Short Ratio	3.33	Perf Half Y	69.85%
Sales	312.30M	P/B	1.60	EPS next Y	-321.51%	ROA	-	Short Interest	8.14M	Perf YTD	-33.28%
Book/sh	7.97	P/C	1.04	EPS next 5Y	-3.74%	ROE	-	52W High	26.78 -52.24%	Perf Year	-47.13%
Cash/sh	12.26	P/FCF	-	EPS past 3/5Y	10.20% -5.32%	ROIC	-10.23%	52W Low	5.90 116.78%	Perf 3Y	-68.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	70.01% 43.71%	Gross Margin	98.21%	Volatility	5.06% 7.28%	Perf 5Y	-47.15%
Dividend TTM	-	EV/Sales	0.14	EPS Y/Y TTM	84.54%	Oper. Margin	-32.44%	ATR (14)	0.73	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.70	Sales Y/Y TTM	105.10%	Profit Margin	-18.73%	RSI (14)	62.76	Recom	2.21
Dividend Gr. 3/5Y	- -	Current Ratio	5.70	EPS Q/Q	-	SMA20	9.97%	Beta	1.89	Target Price	12.31
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	23.88%	Rel Volume	0.39	Prev Close	12.55
Employees	430	LT Debt/Eq	0.01	Earnings	Nov 05 BMO	SMA200	44.80%	Avg Volume	2.45M	Price	12.79
IPO	Sep 27, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	31.12% 50.29%	Trades		Volume	948,536	Change	1.91%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-25	Downgrade	Goldman	Neutral → Sell	$6
Sep-24-25	Downgrade	BofA Securities	Buy → Neutral	$10
Sep-17-25	Resumed	Barclays	Overweight	$16
Jun-02-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
May-05-25	Downgrade	Truist	Buy → Hold	$11
May-02-25	Downgrade	TD Cowen	Buy → Hold
May-02-25	Downgrade	Jefferies	Buy → Hold	$10
Mar-13-25	Downgrade	Goldman	Buy → Neutral	$70 → $15
Mar-12-25	Downgrade	Wedbush	Outperform → Neutral	$57 → $12
Mar-11-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-10-24	Initiated	BTIG Research	Buy	$69
Nov-18-24	Initiated	Stephens	Overweight	$55
Feb-28-24	Reiterated	Oppenheimer	Outperform	$95 → $80
Feb-14-24	Downgrade	Citigroup	Buy → Neutral	$36 → $55
Feb-01-24	Initiated	Goldman	Buy	$70
Dec-19-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$25 → $63
Dec-06-23	Upgrade	Jefferies	Hold → Buy	$40
Nov-20-23	Upgrade	Guggenheim	Neutral → Buy
Oct-23-23	Upgrade	Wedbush	Neutral → Outperform	$27 → $24
Jun-26-23	Resumed	Oppenheimer	Outperform	$95

Show Previous Ratings

Today 08:05AM	Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Nov-26-25 07:00AM	Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-24-25 07:00AM	Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-05-25 02:02PM	Arvinas Inc (ARVN) Q3 2025 Earnings Call Highlights: Clinical Advancements and Strategic ... (GuruFocus.com)
08:20AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:17AM	Earnings To Watch: Arvinas Inc (ARVN) Reports Q3 2025 Result (GuruFocus.com)
Nov-03-25 04:00PM	Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-24-25 04:00PM	Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-23-25 10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-22-25 04:00PM	Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
10:00AM	Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
09:55AM	Loading…
09:55AM	Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet (Zacks)
Oct-20-25 04:15AM	Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy (GlobeNewswire)
Oct-13-25 07:00AM	Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Oct-05-25 02:00PM	Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Oct-01-25 07:00AM	Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire) +7.16%
Sep-25-25 09:40AM	Amazon upgraded, Adobe downgraded: Wall Streets top analyst calls (TipRanks)
Sep-24-25 09:36AM	Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Sep-17-25 04:30PM	Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation (GlobeNewswire)
Aug-29-25 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-23-25 04:18AM	Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco (Insider Monkey)
Aug-17-25 11:41PM	Arvinas, Pfizer's Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment (Insider Monkey)
Aug-08-25 04:05PM	Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer (GlobeNewswire)
Aug-07-25 10:08AM	Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
Aug-06-25 12:16PM	Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles (Zacks) -15.51%
11:51AM	Loading…
11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
11:48AM	RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down (Zacks)
11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:42AM	ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
08:15AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 12:21PM	ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
12:12PM	TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line (Zacks)
10:14AM	What To Expect From Arvinas Inc (ARVN) Q2 2025 Earnings (GuruFocus.com)
Aug-01-25 11:49AM	FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
Jul-31-25 10:48AM	Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat (Zacks)
10:37AM	Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
Jul-30-25 04:05PM	Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
10:23AM	Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales (Zacks)
Jul-24-25 09:10AM	Arvinas, Inc. (ARVN): A Bull Case Theory (Insider Monkey)
Jul-22-25 11:51AM	JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
09:39AM	ALKS Down Despite Positive Top-Line Data From Narcolepsy Study (Zacks)
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks) -5.28%
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-16-25 11:54AM	Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag (Zacks)
Jul-15-25 10:17AM	Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer (Zacks) -5.97%
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
Jul-09-25 07:00AM	Arvinas Announces Retirement of Chief Executive Officer and Succession Plan (GlobeNewswire)
Jun-16-25 09:55AM	Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade (Zacks)
Jun-13-25 07:00AM	Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress (GlobeNewswire)
Jun-06-25 07:00AM	Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer (GlobeNewswire) +8.82%
Jun-05-25 08:28AM	Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting (GlobeNewswire)
May-31-25 08:00AM	Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer (GlobeNewswire)
04:00AM	Full Arvinas, Pfizer data confirm potential, limits of Protac drug in breast cancer (BioPharma Dive)
May-30-25 09:55AM	Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? (Zacks)
07:00AM	Arvinas to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-25 10:29AM	Pfizer and Arvinas gamble to shift breast cancer treatment paradigm (Clinical Trials Arena)
May-28-25 08:00PM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN) (Business Wire) +8.89%
May-04-25 04:17PM	Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case (Seeking Alpha)
May-02-25 09:19AM	Here are 1 Main Capital Partners' Views on Arvinas (ARVN) (Insider Monkey) +6.78%
03:03AM	Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... (GuruFocus.com)
May-01-25 09:40PM	Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript (Seeking Alpha) -24.84%
08:15AM	Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates (Zacks)
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
07:00AM	Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 10:01AM	Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 07:00AM	Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
06:45AM	Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-23-25 10:44AM	Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-21-25 07:00AM	Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-09-25 09:43AM	Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple (Insider Monkey) +8.72%
09:35AM	After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN) (Zacks)
Apr-04-25 03:38PM	Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study (Benzinga)
12:33PM	Arvinas PROTAC halves protein suspected to play role in Parkinsons (Clinical Trials Arena)
07:00AM	Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation (GlobeNewswire)
Mar-27-25 07:00AM	Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases (GlobeNewswire)
Mar-21-25 12:44PM	OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek (Zacks)
12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
12:17PM	PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug (Zacks)
09:26AM	ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia (Zacks)
Mar-20-25 10:19AM	IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success (Zacks)
Mar-19-25 10:59AM	JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease (Zacks)
09:35AM	Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround (Zacks)
Mar-18-25 08:05PM	Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey)
Mar-17-25 09:35AM	Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround (Zacks)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-13-25 10:52AM	Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last? (Zacks) -5.32%
Mar-11-25 04:06PM	Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug (Investor's Business Daily) -52.73% +8.80%
11:43AM	Pfizer and Arvinass HER2-breast cancer drug extends PFS in certain patients (Clinical Trials Arena)
07:45AM	Arvinas gets positive breast cancer data, but finds differentiation a hard sell (BioPharma Dive)
06:45AM	Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial (GlobeNewswire)
Mar-04-25 04:05PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.90%
Mar-03-25 09:55AM	Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know (Zacks) -8.31%

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Loomis David K	Chief Accounting Officer	Nov 07 '25	Sale	9.89	230	2,275	31,697	Nov 07 04:20 PM
Morrison Briggs	Director	Sep 22 '25	Buy	7.57	30,000	227,010	76,021	Sep 24 09:16 AM
Saik Andrew	Chief Financial Officer	Jun 24 '25	Sale	7.61	5,700	43,377	164,401	Jun 24 04:08 PM
Andrew Saik	Officer	Jun 24 '25	Proposed Sale	7.35	5,927	43,593		Jun 23 04:13 PM
Cacace Angela M	Chief Scientific Officer	Jun 17 '25	Sale	7.49	2,583	19,347	154,248	Jun 18 06:04 PM
Berkowitz Noah	Chief Medical Officer	Mar 18 '25	Sale	8.59	8,658	74,372	110,023	Mar 19 08:06 AM
Noah Berkowitz	Officer	Mar 18 '25	Proposed Sale	8.59	8,658	74,372		Mar 18 09:50 PM
Loomis David K	Chief Accounting Officer	Feb 24 '25	Sale	16.75	1,214	20,334	18,863	Feb 25 06:37 AM
Cacace Angela M	Chief Scientific Officer	Feb 24 '25	Sale	16.70	4,207	70,238	97,231	Feb 25 06:35 AM
Taylor Ian	President, R&D	Feb 24 '25	Sale	16.71	9,020	150,752	159,121	Feb 25 06:33 AM
Houston John G	President and CEO	Feb 24 '25	Sale	16.72	31,338	523,881	1,157,480	Feb 25 06:31 AM
Ian Taylor	Officer	Feb 24 '25	Proposed Sale	16.71	9,020	150,730		Feb 24 08:50 PM
John G Houston	Officer	Feb 24 '25	Proposed Sale	16.71	31,338	523,801		Feb 24 08:48 PM
Angela M Cacace	Officer	Feb 24 '25	Proposed Sale	16.69	4,207	70,230		Feb 24 08:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARVN

Arvinas Inc

Upgrade your FINVIZ experience